The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors ...

NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S.

President Prabowo’s Washington messaging pairs a principled stance on Gaza with an unusually direct signal of operational readiness. For Australia, the real question is what this shift means for the ...

The first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon Therapeutics’ lead ...

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this ...

On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 ...

Researchers highlighted the anti-inflammatory benefits of GLP-1 receptor agonists in people with HIV, plus a growing concern over rising STI rates and the cautious promise of doxycycline post-exposure ...

Most people fear a dramatic, painful end. Hospice experience reveals a quieter truth that may ease anxiety and change how you think about death.

The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...

Maintenance therapy with subcutaneous imsidolimab allowed all treated patients to remain flare-free throughout the GEMINI-2 study period.